Cardiac Dysfunction and Arterial Hypertension as Manifestations of Cardiovasculotoxicity of iVEGF-Containing Chemotherapy. Clinical Case

Significant advances in timely diagnosis and modern antitumor therapy have led to a considerable increase in the survival rate of cancer patients. On the other hand, the incidence of cardiovascular (CV) diseases and their complications is increasingly growing, including due to side effects of anticancer drugs. CV complications are the most common cause of non-oncological death of cancer patients. The development of polychemotherapy-induced arterial hypertension (AH) is closely associated with the use of certain groups of drugs, for example, inhibitors of vascular endothelial growth factor (iVEGF). Such AH is generally dose-dependent and reversible after interruption or termination of treatment. However, systemic AH, regardless of its genesis, is one of the key risk factors for many CV events (myocardial infarction, stroke, heart failure, arrhythmias) and kidney disease. Therefore, thorough blood pressure monitoring and its timely and adequate correction if needed are indicated when using certain groups of chemotherapy drugs. This article describes a clinical follow-up of a patient with induced AH associated with the iVEGF antitumor therapy for advanced uterine cancer with a rapid development of left ventricular myocardial dysfunction.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7–33. DOI: 10.3322/caac.21654

2. Ahmed T, Marmagkiolis K, Ploch M, Irizarry-Caro JA, Amatullah A, Desai S et al. The Year in Cardio-oncology 2022. Current Problems in Cardiology. 2023;48(1):101435. DOI: 10.1016/j.cpcardi-ol.2022.101435

3. Essa H, Dobson R, Wright D, Lip GYH. Hypertension management in cardio-oncology. Journal of Human Hypertension. 2020;34(10):673– 81. DOI: 10.1038/s41371-020-0391-8

4. Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. Journal of the American College of Cardiology. 2017;70(20):2536–51. DOI: 10.1016/j.jacc.2017.09.1096

5. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019;280:163–75. DOI: 10.1016/j.ijcard.2019.01.038

6. Cohen JB, Brown NJ, Brown S-A, Dent S, Van Dorst DCH, Herrmann SM et al. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46–57. DOI: 10.1161/HYP.0000000000000224

7. Van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021;128(7):1040–61. DOI: 10.1161/CIRCRESAHA.121.318051

8. Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Kamiimabeppu D, Sato T et al. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy. Cancer Medicine. 2021;10(2):615–25. DOI: 10.1002/cam4.3638

9. Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ, Crocker IR et al. Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer. 2015;121(9):1456–62. DOI: 10.1002/cncr.29234

10. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

11. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

12. Chazova I.E., Vitsenya M.V., Ageev F.T. Cardiovascular complications of antitumor therapy. -M.: GRANAT;2019. - 160p. ISBN 978-5-906456-44-1

13. Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, De Vries T et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–54. DOI: 10.1093/eurheartj/ehab309